{"id":2237,"date":"2017-02-01T15:05:08","date_gmt":"2017-02-01T20:05:08","guid":{"rendered":"https:\/\/med-millerlab.sites.unc.edu\/?p=2237"},"modified":"2018-06-19T14:42:31","modified_gmt":"2018-06-19T18:42:31","slug":"new-glioblastoma-treatment-successfully-tested-with-human-cells","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/2017\/02\/new-glioblastoma-treatment-successfully-tested-with-human-cells\/","title":{"rendered":"New Glioblastoma Treatment Successfully Tested with Human Cells"},"content":{"rendered":"<header>\n<p id=\"description\" class=\".documentDescription\"><em>A new study published today in Science Translational Medicine from the team of Shawn Hingtgen, Ryan Miller, and Matt Ewend at the UNC Eshelman School of Pharmacy and School of Medicine shows that human skin cells converted to neural stem cells deliver therapeutics that inhibit progression of the deadliest adult brain tumor, glioblastoma.<\/em><\/p>\n<\/header>\n<div id=\"viewlet-above-content-body\"><\/div>\n<div id=\"content-area\">\n<div class=\"newsImageContainer somLinkedContent\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-109 alignright\" src=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-content\/uploads\/sites\/455\/2017\/09\/glioblastoma.jpeg\" alt=\"\" width=\"400\" height=\"132\" srcset=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-content\/uploads\/sites\/455\/2017\/09\/glioblastoma.jpeg 400w, https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-content\/uploads\/sites\/455\/2017\/09\/glioblastoma-300x99.jpeg 300w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/div>\n<div id=\"parent-fieldname-text\" class=\"plain\">\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<div id=\"viewlet-below-content-body\">\u00a0Read more about this important discovery in\u00a0<a class=\"external-link\" title=\"\" href=\"http:\/\/www.unc.edu\/spotlight\/unc-chapel-hill-researchers-reach-critical-milestone-treating-brain-cancer\/\" target=\"_self\">UNC Spotlights<\/a>,\u00a0<a class=\"external-link\" title=\"\" href=\"https:\/\/unclineberger.org\/news\/revolutionary-approach\" target=\"_self\">Lineberger Pathways<\/a>, at the\u00a0<a class=\"external-link\" title=\"\" href=\"https:\/\/pharmacy.unc.edu\/new-unc-brain-tumor-treatment-successfully-tested-human-cells\/\" target=\"_self\">UNC School of Pharmacy<\/a>, and at\u00a0<a class=\"external-link\" title=\"\" href=\"http:\/\/stm.sciencemag.org\/content\/9\/375\/eaah6510\" target=\"_self\">Science Translational Medicine<\/a>.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A new study published today in Science Translational Medicine from the team of Shawn Hingtgen, Ryan Miller, and Matt Ewend at the UNC Eshelman School of Pharmacy and School of Medicine shows that human skin cells converted to neural stem cells deliver therapeutics that inhibit progression of the deadliest adult brain tumor, glioblastoma. &nbsp; \u00a0Read &hellip; <a href=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/2017\/02\/new-glioblastoma-treatment-successfully-tested-with-human-cells\/\" aria-label=\"Read more about New Glioblastoma Treatment Successfully Tested with Human Cells\">Read more<\/a><\/p>\n","protected":false},"author":2049,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-2237","post","type-post","status-publish","format-standard","hentry","category-news","odd"],"acf":[],"featured_image":false,"featured_image_medium":false,"featured_image_medium_large":false,"featured_image_large":false,"featured_image_thumbnail":false,"featured_image_alt":false,"category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/category\/news\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/posts\/2237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/users\/2049"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/comments?post=2237"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/posts\/2237\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/media?parent=2237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/categories?post=2237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/tags?post=2237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}